Global Disposable Intravenous Products and Lyophilized Injectable Drugs Markets Forecast to 2033

The global disposable intravenous products market was valued at USD 3.16 billion in 2025 and is projected to reach USD 4.99 billion by 2033, growing at a 5.9 % CAGR. Key drivers include the rising prevalence of chronic diseases, increasing surgical procedures, and a shift toward single‑use devices for infection control. Major manufacturers such as B. Braun, Baxter, Becton Dickinson, ICU Medical, Smiths Medical, Terumo, NIPRO, Fresenius Kabi, Moog and Vygon are expanding product portfolios and geographic reach.

The lyophilized injectable drugs market stood at USD 3.39 billion in 2024 and is expected to climb to USD 5.49 billion by 2032, at a 6.2 % CAGR. Growth is driven by expanding oncology treatments, broader use of monoclonal antibodies, and heightened demand for stable, injectable biologics. Leading players include Pfizer, Novartis, Sanofi, Fresenius Kabi and AbbVie, which are pursuing mergers, acquisitions and new product launches to capture emerging market opportunities.